Pediatric AML patient characteristics
| Characteristics . | All patients . | Low VEGFC . | High VEGFC . |
|---|---|---|---|
| No. of patients | 100 | 50 | 50 |
| Median age, y (range) | 9.0 (0.0-16.7) | 10 (0.0-15.0) | 8.0 (0.6-16.7) |
| Median WBC, ×109/L (range) | 36.5 (2.3-483) | 33.8 (2.5-320) | 46.7 (2.3-483) |
| Cytogenetic risk | |||
| Favorable | 25 (25%) | 15 (30%) | 10 (20%) |
| t(8;21) | 14 | 9 | 5 |
| t(15;17) | 4 | 2 | 2 |
| inv16 | 7 | 4 | 3 |
| Intermediate | 58 (58%) | 27 (54%) | 31 (62%) |
| Normal karyotype | 16 | 10 | 6 |
| Other | 39 | 16 | 23 |
| +8 | 3 | 1 | 2 |
| Unfavorable | 12 (12%) | 6 (12%) | 6 (12%) |
| Complex | 10 | 6 | 4 |
| −5(q)/−7(q) | 2 | — | 2 |
| Not available | 5 (5%) | 2 (4%) | 3 (6%) |
| CR vs no CR | 79/21 | 44/6* | 35/15* |
| Relapse | 40 | 23 | 17 |
| Dead vs alive | 48/52 | 20/30 | 28/22 |
| Characteristics . | All patients . | Low VEGFC . | High VEGFC . |
|---|---|---|---|
| No. of patients | 100 | 50 | 50 |
| Median age, y (range) | 9.0 (0.0-16.7) | 10 (0.0-15.0) | 8.0 (0.6-16.7) |
| Median WBC, ×109/L (range) | 36.5 (2.3-483) | 33.8 (2.5-320) | 46.7 (2.3-483) |
| Cytogenetic risk | |||
| Favorable | 25 (25%) | 15 (30%) | 10 (20%) |
| t(8;21) | 14 | 9 | 5 |
| t(15;17) | 4 | 2 | 2 |
| inv16 | 7 | 4 | 3 |
| Intermediate | 58 (58%) | 27 (54%) | 31 (62%) |
| Normal karyotype | 16 | 10 | 6 |
| Other | 39 | 16 | 23 |
| +8 | 3 | 1 | 2 |
| Unfavorable | 12 (12%) | 6 (12%) | 6 (12%) |
| Complex | 10 | 6 | 4 |
| −5(q)/−7(q) | 2 | — | 2 |
| Not available | 5 (5%) | 2 (4%) | 3 (6%) |
| CR vs no CR | 79/21 | 44/6* | 35/15* |
| Relapse | 40 | 23 | 17 |
| Dead vs alive | 48/52 | 20/30 | 28/22 |
Cytogenetic risk group distinction (favorable, intermediate, and unfavorable) is described in “Patients.”
“Low VEGFC” indicates a VEGFC mRNA expression level below the median VEGFC level; high VEGFC, a VEGFC mRNA expression level above the median VEGFC level; and CR, complete remission.
A significant difference when AML patients with a low versus high VEGFC expression level were compared (P < .01).